{
  "nodes": [
    {
      "id": "node_001",
      "content": "ROS1 rearrangement",
      "parent_ids": [],
      "children_ids": [
        "node_002",
        "node_006"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "nn"
      ]
    },
    {
      "id": "node_002",
      "content": "ROS1 rearrangement discovered prior to first-line systemic therapy",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_003"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_003",
      "content": "Preferred Crizotinib or Entrectinib or Repotrectinib",
      "parent_ids": [
        "node_002"
      ],
      "children_ids": [
        "node_004"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "ss",
        "ooo",
        "rr"
      ]
    },
    {
      "id": "node_004",
      "content": "Progression",
      "parent_ids": [
        "node_003"
      ],
      "children_ids": [
        "node_005"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "yy"
      ]
    },
    {
      "id": "node_005",
      "content": "Subsequent Therapy",
      "parent_ids": [
        "node_004"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-31"
      ],
      "footnote_labels": [
        "rr"
      ]
    },
    {
      "id": "node_006",
      "content": "ROS1 rearrangement discovered during first-line systemic therapy",
      "parent_ids": [
        "node_001"
      ],
      "children_ids": [
        "node_007"
      ],
      "tree_ids": [],
      "footnote_labels": []
    },
    {
      "id": "node_007",
      "content": "Interrupt current therapy and start Crizotinib (preferred) or Entrectinib (preferred) or Repotrectinib (preferred)",
      "parent_ids": [
        "node_006"
      ],
      "children_ids": [
        "node_008"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "xx",
        "ooo",
        "rr"
      ]
    },
    {
      "id": "node_008",
      "content": "Progression",
      "parent_ids": [
        "node_007"
      ],
      "children_ids": [
        "node_009"
      ],
      "tree_ids": [],
      "footnote_labels": [
        "yy"
      ]
    },
    {
      "id": "node_009",
      "content": "Subsequent Therapy",
      "parent_ids": [
        "node_008"
      ],
      "children_ids": [],
      "tree_ids": [
        "NSCL-31"
      ],
      "footnote_labels": [
        "rr"
      ]
    }
  ],
  "tree_references": [
    {
      "from_tree": "NSCL-30",
      "to_tree": "NSCL-31",
      "description": "Subsequent Therapy for progression"
    },
    {
      "from_tree": "NSCL-30",
      "to_tree": "NSCL-H",
      "description": "Principles of Molecular and Biomarker Analysis"
    },
    {
      "from_tree": "NSCL-30",
      "to_tree": "NSCL-J",
      "description": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease"
    }
  ],
  "footnotes": [
    {
      "label": "nn",
      "content": "Principles of Molecular and Biomarker Analysis (NSCL-H)."
    },
    {
      "label": "rr",
      "content": "Molecular or Biomarker-Directed Therapy for Advanced or Metastatic Disease (NSCL-J)."
    },
    {
      "label": "ss",
      "content": "For PS 0\u20134."
    },
    {
      "label": "xx",
      "content": "If there is a good response to current therapy, it is reasonable to continue therapy."
    },
    {
      "label": "yy",
      "content": "Beware of flare phenomenon in subset of patients who discontinue TKI. If disease flare occurs, restart TKI."
    },
    {
      "label": "ooo",
      "content": "Entrectinib or repotrectinib may be better for patients with brain metastases."
    }
  ],
  "extraction_confidence": 0.95,
  "image_title": "ROS1 REARRANGEMENT",
  "tree_id": "NSCL-30"
}